Research Analysts Offer Predictions for EHC Q1 Earnings

Encompass Health Co. (NYSE:EHC - Free Report) - Research analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Encompass Health in a report issued on Wednesday, January 8th. Zacks Research analyst Z. Masood now expects that the company will post earnings per share of $1.23 for the quarter, down from their prior estimate of $1.25. The consensus estimate for Encompass Health's current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Encompass Health's Q2 2025 earnings at $1.21 EPS, FY2025 earnings at $4.73 EPS, Q1 2026 earnings at $1.33 EPS, Q3 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.30 EPS and FY2026 earnings at $5.27 EPS.

Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.09. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the previous year, the business earned $0.86 earnings per share. Encompass Health's quarterly revenue was up 11.9% compared to the same quarter last year.

EHC has been the subject of a number of other reports. Barclays raised their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 29th. Truist Financial reissued a "buy" rating and set a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Royal Bank of Canada upped their price objective on Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. KeyCorp lifted their price objective on Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 29th. Finally, UBS Group boosted their target price on shares of Encompass Health from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $107.11.

Encompass Health Price Performance

NYSE:EHC traded up $1.49 during mid-day trading on Monday, hitting $92.54. 529,122 shares of the company's stock traded hands, compared to its average volume of 631,217. Encompass Health has a 1 year low of $67.94 and a 1 year high of $104.55. The company has a market cap of $9.32 billion, a PE ratio of 22.35, a price-to-earnings-growth ratio of 1.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The firm's 50 day simple moving average is $98.23 and its 200 day simple moving average is $93.78.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.73%. The ex-dividend date is Thursday, January 2nd. Encompass Health's dividend payout ratio (DPR) is 16.43%.

Hedge Funds Weigh In On Encompass Health

Hedge funds have recently made changes to their positions in the stock. TD Private Client Wealth LLC boosted its holdings in Encompass Health by 2,870.0% in the third quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company's stock valued at $709,000 after acquiring an additional 7,089 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Encompass Health by 532.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company's stock worth $4,860,000 after purchasing an additional 42,338 shares during the period. Pathstone Holdings LLC lifted its stake in shares of Encompass Health by 54.5% in the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company's stock valued at $2,032,000 after purchasing an additional 7,412 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Encompass Health during the 2nd quarter worth about $541,000. Finally, Meeder Asset Management Inc. increased its position in Encompass Health by 43.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company's stock worth $6,417,000 after purchasing an additional 20,242 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.